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Abstract
α-Synuclein aggregation is implicated in several neurodegenerative diseases, including Parkinson’s disease
(PD) and dementia with Lewy Bodies (DLB). Changes in cellular signaling pathways induced by this
aggregation may contribute to cell death and disease pathogenesis. To investigate this, we used quantitative
proteomics to measure the relative abundance changes of the proteome and phosphoproteome in response to
aggregation of endogenous α-synuclein in the brain of a mouse model. Aggregation in this model is induced
by the intrastriatal injection of α-synuclein pre-formed fibrils and recapitulates several cardinal features of
human PD, including progressive aggregation concomitant with dopaminergic degeneration and motor
symptoms. We quantified the relative abundance changes of 5,290 proteins and 2,763 phosphosites in
wildtype mice and found significant changes in vesicle-mediated transport, RNA processing and the immune
response. The immunoproteasome, an altered form of the constitutive proteasome that is induced in response
to stress, was elevated in response to α-synuclein aggregation. Increased levels and activity of the
immunoproteasome were found in human DLB compared with age-matched healthy controls. Additionally,
the immunoproteasome degrades α-synuclein fibrils more efficiently than the constitutive proteasome. This is
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α-Synuclein	 is	 a	 conserved,	 abundantly	 expressed	 protein	 that	 is	 partially	 localized	 in	 pre-
synaptic	 terminals	 in	 the	 central	 nervous	 system.	 	 The	 precise	 biological	 function(s)	 and	
structure	 of	 α-synuclein	 are	 under	 investigation.	 	 Recently,	 the	 native	 conformation	 and	 the	
presence	 of	 naturally	 occurring	 multimeric	 assemblies	 have	 come	 under	 debate.	 	 These	 are	
important	deliberations	because	α-synuclein	assembles	into	highly	organized	amyloid-like	fibrils	
and	non-amyloid	amorphous	aggregates	 that	 constitute	 the	neuronal	 inclusions	 in	Parkinson’s	
disease	 and	 related	 disorders.	 	 Therefore	 understanding	 the	 nature	 of	 the	 native	 and	
pathological	 conformations	 is	 pivotal	 from	 the	 standpoint	 of	 therapeutic	 interventions	 that	
could	maintain	α-synuclein	in	its	physiological	state.		In	this	review,	we	will	discuss	the	existing	




α-Synuclein	 is	 a	 soluble	 protein	 that	 is	 highly	 conserved	 in	 vertebrates	 and	 abundantly	
expressed	 in	nervous	 tissue	 (Jakes	et	 al.,	 1994).	 	 It	was	 first	discovered	 in	1988	 in	 association	
with	 purified	 synaptic	 vesicles	 from	 the	 Torpedo	 electric	 ray	 (Maroteaux	 et	 al.,	 1988).	 	 Soon	
afterward	 α-synuclein	 was	 found	 to	 be	 widely	 distributed	 across	 the	 mammalian	 brain	 and	
localized	to	presynaptic	nerve	terminals,	suggesting	functions	related	to	neurotransmission	(Iwai	
et	 al.,	 1995).	 	 Independent	 of	 these	 reports,	 α-synuclein	was	 identified	 as	 the	 precursor	 to	 a	





also	 dynamically	 regulated	 during	 song	 learning	 in	 zebra	 finch,	 supporting	 a	 role	 in	 synaptic	
plasticity	(George	et	al.,	1995).			
The	 discovery	 of	 a	 mutation	 in	 the	 α-synuclein	 gene	 that	 was	 associated	 with	 autosomal	
dominant	 inheritance	of	Parkinson’s	disease	 (PD)	provided	 the	 impetus	 for	 a	major	 shift	 in	α-
synuclein	research	(Polymeropoulos	et	al.,	1997).		PD	is	a	neurodegenerative	disorder	primarily	
characterized	by	the	loss	of	dopamine-producing	neurons	in	the	substantia	nigra	pars	compacta	
resulting	 in	 motor	 impairment.	 	 Since	 the	 original	 publication	 of	 the	 A53T	 mutation,	 several	
mutations,	as	well	as	multiplications	of	the	α-synuclein	gene	have	been	linked	to	PD	(Chartier-
Harlin	et	al.,	2004;	Krüger	et	al.,	1998;	Lesage	et	al.,	2013;	Pasanen	et	al.,	2014;	Proukakis	et	al.,	
2013;	 Singleton	 et	 al.,	 2003;	 Zarranz	 et	 al.,	 2004;	 Ferese	 et	 al.	 2015)	 	 Furthermore,	 several	
antibodies	against	α-synuclein	robustly	detect	the	well-known	pathoanatomical	features	of	PD,	
Lewy	bodies	and	Lewy	neurites,	 in	postmortem	brain	tissue	from	patients	with	sporadic	PD	as	
well	 as	 other	 related	 neurodegenerative	 disorders	 (Baba	 et	 al.,	 1998;	 Spillantini	 et	 al.,	 1997;	
Takeda	 et	 al.,	 1998).	 	 The	 finding	 that	wildtype	α-synuclein	was	 detected	 in	 Lewy	bodies	 and	
Lewy	neurites	prompted	the	publication	of	numerous	studies	that	investigated	the	biochemistry	
and	 biology	 of	 α-synuclein.	 	 Despite	 the	 rather	 impressive	 body	 of	work	 several	 fundamental	
questions	 remain:	What	 is	 the	physiological	 function	of	α-synuclein?	 	What	 is	 the	structure	of	
native	 α-synuclein?	 	 What	 factors	 contribute	 to	 the	 induction	 of	 aggregation-competent	
conformational	states	of	α-synuclein?		In	this	review,	we	will	briefly	review	the	evidence	for	the	








The	 initial	 studies	 indicated	 that	 α-synuclein	 is	 not	 required	 for	 neuronal	 development	 or	
synapse	 formation,	 but	 instead	 may	 modulate	 synaptic	 activity.	 	 In	 rodents,	 α-synuclein	 is	
detected	close	 to	 the	time	of	birth	and	continues	 to	 increase	until	one	month	of	age,	when	 it	
reaches	a	steady-state	 level	that	 is	maintained	throughout	adulthood	(Shibayama-Imazu	et	al.,	
1993).	 	 Similarly,	 in	 cultured	 rat	 neurons	 the	 development	 of	 synapses	 precedes	 α-synuclein	
expression	and	translocation	to	axonal	terminals	(Murphy	et	al.,	2000;	Withers	et	al.,	1997).		The	
hypothesis	 that	 α-synuclein	 regulates	 synaptic	 activity	 was	 directly	 tested	 in	 mice	 lacking	 α-
synuclein.	 	α-Synuclein	null	mice	develop	normal	brain	architecture	and	synaptic	contacts,	and	
do	 not	 exhibit	 gross	 behavioral	 phenotypes	 (Abeliovich	 et	 al.,	 2000).	 	 However,	 subtle	








synaptic	 dysfunction	 compared	with	wildtype	mice	 (Burré	 et	 al.,	 2010;	Greten-Harrison	 et	 al.,	
2010).	 	Triple	knockouts	 in	another	study	had	motor	deficits	and	decreased	striatal	dopamine,	








in	 vivo	and	 in	 vitro	 induces	a	 significant	 loss	of	undocked	 synaptic	 vesicles,	 suggesting	 that	α-
synuclein	 acts	 to	 replenish	 or	maintain	 the	 resting	 and/or	 reserve	 vesicle	 pools	 (Cabin	 et	 al.,	




a	decrease	or	no	 change	 in	 the	number	of	 docked	 vesicles	 (Cabin	et	 al.,	 2002;	Murphy	et	 al.,	
2000).		Conversely	α-synuclein	expression	in	PC12	cells	causes	an	accumulation	of	vesicles	at	the	
plasma	 membrane	 and	 impairment	 of	 exocytosis	 (Larsen	 et	 al.,	 2006).	 	 However,	 in	 mice	
modestly	overexpressing	α-synuclein	(levels	are	not	associated	with	neurotoxicity),	hippocampal	
synapses	display	a	redistribution	of	vesicles	away	from	the	active	zone.		The	density	of	vesicles	
in	 synaptic	boutons	 is	 also	 reduced,	 consistent	with	α-synuclein-mediated	 inhibition	of	 vesicle	
clustering.	 	 This	 is	 supported	 by	 α-synuclein-induced	 defects	 in	 vesicle	 re-clustering	 following	
endocytosis	in	rat	hippocampal	neurons	(Nemani	et	al.,	2010).		Still,	opposing	results	have	been	
obtained	 from	 yeast,	 in	 which	 α-synuclein	 expression	 results	 in	 massive	 accumulations	 of	
vesicles	that	co-localize	with	Rab	GTPases	(Gitler	et	al.,	2008;	Soper	et	al.,	2008).	 	Likewise,	α-
synuclein	 has	 been	 shown	 to	 restrict	 vesicle	 diffusion	 away	 from	 synapses	 in	 mouse	






Chaperone-like	 activity	 and	 neurotransmitter	 release.	 	 α-Synuclein	 and	 the	 other	 synuclein	
family	 members	 may	 act	 as	 molecular	 chaperones,	 facilitating	 neurotransmitter	 release.		
Cysteine-string	protein	α	(CSPα)	is	a	chaperone	that	is	essential	for	synaptic	health;	its	deletion	
in	mice	 leads	 to	a	decrease	 in	 SNARE	protein	 complexes,	nerve	 terminal	degeneration,	motor	
impairment	and	death.	 	When	expressed	 in	CSPα-deficient	mice,	α-synuclein	 is	 able	 to	 rescue	
this	 degenerative	 phenotype	 and	 restore	 levels	 of	 SNARE	 complexes	 in	 synaptic	 terminals.		
Moreover,	mice	 lacking	both	α-synuclein	and	CSPα	exhibit	 an	exacerbated	phenotypic	decline	
(Chandra	 et	 al.,	 2005).	 	 These	 findings	 suggest	 that	 α-synuclein	 is	 able	 to	 complement	 the	
activity	 of	 CSPα	 in	 promoting	 synapse	 integrity.	 	 Direct	 evidence	 for	 the	 interaction	 of	 α-
synuclein	 with	 SNARE	 complexes	 was	 documented	 by	 co-immunoprecipitation	 of	 α-synuclein	
with	 SNARE	 proteins	 and	 specific	 binding	 to	 the	 vesicle-associated	 SNARE	 protein	
synaptobrevin-2.	 	 In	 mammalian	 cells	 and	 purified	 in	 vitro	 systems,	 α-synuclein	 dose-
dependently	 facilitates	 SNARE	 complex	 assembly	 (Burré	 et	 al.,	 2010).	 	 Additional	 support	 for	




like	 function	 of	 synucleins	 and	 the	 existence	 of	 several	 protein-protein	 interactions	 that	
facilitate	synaptic	function.	
Putative	role	 in	neurotransmitter	synthesis	and	reuptake.	 	Published	evidence	 indicates	that	α-
synuclein-mediated	 protein-protein	 interactions	 may	 modulate	 dopamine	 synthesis	 and	
recycling.	 	 α-Synuclein	 may	 inhibit	 the	 activity	 of	 tyrosine	 hydroxylase	 (TH),	 the	 rate-limiting	





and	 PC12	 cells,	 potentially	 through	 PP2A	 phosphatase-mediated	 reduction	 of	 serine	 40	
phosphorylation	of	TH	(Peng	et	al.,	2005;	Perez	et	al.,	2002).		α-Synuclein	may	also	interact	with	
and	inhibit	the	activity	of	aromatic	amino	acid	decarboxylase,	which	catalyzes	the	conversion	of	
L-DOPA	 to	 dopamine	 (Tehranian	 et	 al.,	 2006).	 	 Thus,	 α-synuclein	 may	 serve	 as	 a	 negative	
regulator	 of	 dopamine	 synthesis,	 though	 further	 validation	 of	 these	 findings	 is	 necessary.		
Several	reports	have	also	implicated	α-synuclein	in	the	regulation	of	the	dopamine	transporter	
(DAT),	 though	 the	evidence	 is	 conflicting	with	 regards	 to	 the	 functional	 consequences.	 	Direct	
binding	of	α-synuclein	to	DAT	has	been	demonstrated	in	multiple	studies.		However,	α-synuclein	
does	not	 appear	 to	alter	DAT	 function,	but	 rather	 in	 various	 cellular	 contexts	 can	promote	or	




Primary	 sequence.	 	 The	 primary	 sequence	 of	 α-synuclein	 consists	 of	 140	 amino	 acids	 with	 a	
predicted	 molecular	 mass	 of	 14,460.16	 Da	 and	 an	 isoelectric	 point	 of	 4.67	 (figure	 1).	 	 The	
sequence	 of	 α-synuclein	 is	 composed	 of	 three	 functionally	 defined	 domains.	 	 The	 N-terminal	
region	 (amino	 acids	 1-60)	 is	 characterized	 by	 the	 presence	 of	 unique	 and	 highly	 conserved	








arrangement	with	 a	 short	 linking	 region	 (Ulmer	 et	 al.,	 2005).	 	 These	 helices	 are	 stabilized	 by	
interaction	with	 a	 variety	 of	 phospholipid	 bilayers,	 though	α-synuclein	 interacts	 preferentially	
with	 membranes	 of	 high	 curvature	 and	 an	 abundance	 of	 acidic	 phospholipids,	 properties	
consistent	 with	 those	 of	 synaptic	 vesicles	 (Davidson	 et	 al.,	 1998;	 Zhu	 et	 al.,	 2003).	 	 Upon	
interaction	with	membranes	of	low	curvature	α-synuclein	adopts	a	distinct	secondary	structure	
characterized	by	a	single	extended	helix	that	includes	both	previously	described	helical	domains	
and	the	 linker	 region	 (amino	acids	38-44)	 (Ferreon	et	al.,	2009;	Georgieva	et	al.,	2010;	Trexler	
and	Rhoades,	2009).		All	known	mutations	associated	with	familial	PD	(A30P,	E46K,	H50Q,	G51D,	
A53E,	and	A53T)	are	 found	 in	 the	N-terminal	domain	 (Krüger	et	al.,	2008;	 Lesage	et	al.,	2013;	
Pasanen	et	al.,	2014;	Polymeropoulos	et	al.,	1997;	Proukakis	et	al.,	2013;	Zarranz	et	al.,	2004).		
These	mutations,	with	 the	 exception	 of	G51D,	 A53E,	 and	A30P,	 increase	 the	 propensity	 of	 α-
synuclein	to	form	insoluble	aggregates	and	produce	morphologically	distinct	aggregate	species	
(Ghosh	et	al.,	 2014;	Giasson	et	al.,	 1999;	Greenbaum	et	al.,	 2005;	 Lesage	et	al.,	 2013;	Mahul-
Mellier	 et	 al.,	 2015;	 Narhi	 et	 al.,	 1999).	 	 Though	 the	 precise	 mechanism	 by	 which	 these	




Amino	 acids	 61-95	 compose	 the	 hydrophobic	 NAC	 domain	 (Uéda	 et	 al.,	 1993).	 	 This	 region	
contains	 a	 sequence	 of	 amino	 acids	 (71-82)	 necessary	 and	 sufficient	 for	 α-synuclein	 self-
assembly	 into	amyloid	fibrils	 (Giasson	et	al.,	2001).	 	Recently	the	crystal	structures	of	residues	







and	 5	 aspartate	 residues)	 and	 was	 originally	 proposed	 to	 be	 essential	 for	 maintaining	 the	
solubility	of	the	protein.	 	The	presence	of	5	proline	residues,	which	are	known	to	induce	turns	
and	 disrupt	 secondary	 protein	 structure,	 suggested	 that	 this	 region	 is	 devoid	 of	 secondary	
structure	(George	et	al.,	1995;	Ulmer	et	al.,	2005).		However,	the	C-terminus	was	shown	to	form	
transient,	 long-range	 interactions	 with	 the	 N-terminus	 resulting	 in	 the	 formation	 of	 multiple	
compact	 monomeric	 structures	 (Bertoncini	 et	 al.,	 2005a;	 Dedmon	 et	 al.,	 2005).	 	 These	
compacted	structures	of	α-synuclein	are	temperature	sensitive	and	are	resistant	to	aggregation.		
The	 data	 also	 indicated	 that	 at	 elevated	 temperatures	 the	 C-terminus	 assumes	 an	 extended	
conformation	that	 liberates	N-terminal	associations	and	enables	aggregation	(Bertoncini	et	al.,	
2005b;	Dedmon	et	al.,	2005).		Moreover,	C-terminally	truncated	forms	of	α-synuclein	aggregate	
faster	 than	 full	 length	 protein	 (Hoyer	 et	 al.,	 2004;	 Li	 et	 al.,	 2005).	 	 Truncated	α-synuclein	 has	
been	 detected	 in	 the	 brains	 of	 both	 control	 (non-disease)	 and	 PD	 patients.	 	 Cleavage	 of	 full-
length	protein	at	 residues	D115,	D119,	N122,	D125	and	Y133	was	documented	 in	α-synuclein	
extracted	from	LBs	(Anderson	et	al.,	2006).		









aggregation,	 raising	 the	 question	 of	 metal	 binding	 at	 different	 points	 during	 the	 aggregation	
process	 (Kostka	et	 al.,	 2008).	 	 Cu(II)	 is	 unique	among	metals	 at	 accelerating	aggregation	of	α-
synuclein	 at	 physiologically	 relevant	 concentrations.	 	 The	 sole	 histidine	 residue	 H50	 in	 α-
synuclein	was	 found	to	be	critical	 for	Cu(II)	binding	(Rasia	et	al.,	2005)	whereas	other	divalent	
metal	 ions,	 including	Mn(II),	Co(II),	Ni(II)	and	Fe(II),	preferentially	bind	 to	 the	C-terminus	of	α-
synuclein	at	residues	D121,	N122,	and	E123	(Binolfi	et	al.,	2006).			
Post-translational	 modifications.	 	 α-Synuclein	 undergoes	 a	 number	 of	 post-translational	
modifications,	 including	 N-terminal	 acetylation,	 serine	 and	 tyrosine	 phosphorylation,	 lysine	
ubiquitination	 and	 tyrosine	 nitration	 (Oueslati	 et	 al.,	 2010;	 Barrett	&	Greenamayer	 2015).	 	 α-
Synuclein	 purified	 under	 mild	 conditions	 is	 acetylated	 in	 the	 N-terminus.	 	 The	 N-terminal	
acetylation	may	account	for	the	formation	of	an	oligomeric	form	of	the	protein	with	partial	α-
helical	 structure	 (Trexler	 and	 Rhoades,	 2012).	 	 However,	 semisynthetic	 production	 of	 N-
terminally	acetylated	α-synuclein	demonstrated	 that	modified	and	unmodified	versions	of	 the	






bodies	 was	 phosphorylated	 at	 S129	 (Fujiwara	 et	 al.,	 2002).	 	 An	 antibody	 raised	 against	










that	 phosphorylation	 may	 be	 a	 neuroprotective	 mechanism	 to	 accelerate	 clearance	 of	




for	 mono-	 and	 di-ubiquitination.	 	 It	 has	 long	 been	 established	 that	 the	 core	 of	 Lewy	 bodies	
stains	 positive	 for	 both	 α-synuclein	 and	 ubiquitin	 whereas	 the	 surrounding	 halo	 is	
immunoreactive	 for	 α-synuclein	 (Hasegawa	 et	 al.,	 2002).	 	 Of	 the	 15	 lysine	 residues	 in	 α-




of	 S129	 did	 not	 affect	 secondary	 structure,	 such	 that	 both	 non-phosphorylated	 and	
phosphorylated	 S129	 exhibited	 random	 coil	 structure	 (Paleologou	 et	 al.,	 2008).	 	 NMR	 data	
revealed	 a	 number	 of	 chemical	 shifts	 that	 occur	 due	 to	 phosphorylation.	 	While	 the	 residues	
surrounding	S129	exhibited	 the	greatest	perturbation,	 residues	1-90	also	exhibited	detectable	






two	 common	 phosphomimics	 used	 to	 study	 the	 structural	 consequences	 of	 phosphorylation.		
For	 example,	 phosphorylation	 at	 S129	 increased	 the	 hydrodynamic	 radius	 of	 the	 protein,	
whereas	S129	E/D	mutants	did	not	(Paleologou	et	al.,	2008).			
Subsequent	 studies	 found	 additional	 sites	 of	 phosphorylation.	 	 Elevated	 levels	 of	
phosphorylated	 α-synuclein	 at	 residue	 S87	 were	 detected	 in	 human	 brains	 with	 Alzheimer’s	
disease,	 Lewy	 Body	 disorders,	 and	 multiple	 system	 atrophy	 (Paleologou	 et	 al.,	 2010).	 	 S87	
phosphorylation	 alters	 the	 biophysical	 properties	 of	 α-synuclein,	 including	 inhibition	 of	 fibril	
formation	 and	 reduction	 in	 membrane	 binding	 (Paleologou	 et	 al.,	 2010).	 	 Additionally,	
phosphorylated	 α-synuclein	 at	 residue	 Y125	 was	 detected	 in	 Drosophila	 expressing	 human	
wildtype	 α-synuclein	 as	 well	 as	 in	 human	 brains,	 though	 levels	 were	 decreased	 in	 disease	
compared	with	aged-matched	healthy	controls	(Chen	et	al.,	2009).	
The	 proximity	 of	 the	 α-synuclein	 phosphorylation	 sites	 to	 the	 metal	 binding	 sites	 raised	 the	
question	of	 how	phosphorylation	may	affect	metal	 ion	 interactions.	 	 This	was	 investigated	by	
the	 use	 of	 C-terminal	 peptides	 containing	 residues	 119-132	 that	 were	 either	 unmodified,	
phosphorylated	 at	 Y125	 or	 at	 S129	 (Liu	 and	 Franz,	 2005).	 	 By	 exploiting	 the	 luminescence	




at	 Y125	 or	 S129	were	 tested	 for	 their	 affinity	 to	 various	metal	 ions.	 	 By	 using	 a	 fluorescence	
quenching	 assay,	 the	 dissociation	 constants	 of	 the	 metal	 ion	 complexes	 and	 the	 α-synuclein	






affinity	 than	 phosphorylated	 Y125.	 	 Additionally,	 tandem	 MS	 indicated	 that	 phosphorylation	
causes	the	metal	ion	binding	sites	to	shift	towards	the	C-terminal	end	of	α-synuclein	(Lu	et	al.,	
2011).	
α-Synuclein	within	 Lewy	bodies	 is	 nitrated	on	all	 four	 tyrosine	 residues	 (Giasson	et	 al.,	 2000).		
Chemical	nitration	of	α-synuclein	 results	 in	 the	 formation	of	both	 tyrosine	nitrated	monomers	
and	nitrated	dimers	(Souza	et	al.	2000b).		Immunoelectron	microscopy	confirmed	that	nitrated	
monomers	 and	 dimers	 are	 incorporated	 into	 amyloid	 fibrils.	 	 Purified	 nitrated	 α-synuclein	
monomer	 by	 itself	 was	 unable	 to	 form	 fibrils,	 whereas	 the	 nitrated	 dimer	 accelerated	
aggregation	of	unmodified	α-synuclein	 (Hodara	et	al.,	2004).	 	Additionally,	nitration	at	 residue	
Y39	 in	the	N-terminus	decreased	binding	to	synthetic	vesicles	and	prevented	the	protein	from	
adopting	 α-helical	 conformation	 (Hodara	 et	 al.,	 2004).	 	 These	 observations	 were	 recently	
confirmed	 and	 elegantly	 expanded	 by	 the	 generation	 of	 site-specifically	 nitrated	 α-synuclein	
using	 protein	 semisynthetic	 chemistries	 (Burai	 et	 al.	 2015).	 	 Using	 the	 synthetic	 nitrated	 α-
synuclein	the	data	showed	that	nitration	did	not	interfere	with	phosphorylation	of	S129	by	PLK3	
and	 reaffirmed	 that	 intermolecular	 interactions	 between	 the	 N-	 and	 C-terminal	 regions	 of	 α-
synuclein	 are	 critical	 in	 directing	 nitration-induced	 oligomerization	 of	 α-synuclein	 (Burai	 et	 al.	
2015).			
Native	 conformation(s)	 of	 α-synuclein.	 	 Figure	 2	 depicts	 the	 rapid	 growth	 in	 the	 number	 of	
publications	 identified	 in	 PubMed	 using	 the	 term	 synuclein	 and	 highlights	 key	 studies	 that	
explored	the	native	structure	and	conformation	of	the	protein.		Early	biochemical	studies	of	α-
synuclein	isolated	from	bacterial	expression	systems	or	α-synuclein	expressed	in	rodent	tissues	




α-synuclein	 purified	without	 heating	 on	 6,	 10,	 or	 14%	 acrylamide	 gels	 estimated	 an	 apparent	
molecular	weight	of	20±3	kDa.		However,	the	values	of	sedimentation	coefficient	(S20,w	=	1.7S),	
stokes	radius	(34	Å),	analysis	on	native	gels	and	derivation	of	the	frictional	coefficient	(f/fo=2.09)	
indicated	 an	 apparent	 molecular	 weight	 in	 the	 range	 57-58	 kDa	 (Weinreb	 et	 al.,	 1996).	 	 To	
reconcile	 this	 apparently	 anomalous	 behavior	 it	 was	 proposed	 that	 monomeric	 α-synuclein	
achieves	 minimal	 structure	 in	 simple	 solutions	 and	 this	 rather	 extended	 unstructured	
conformation	 resembles	 a	 globular	 protein	 with	 a	 larger	 apparent	 molecular	 weight.	 	 This	
assumption	was	further	corroborated	by	examination	of	purified	monomeric	α-synuclein	by	CD,	
FTIR	 and	 small	 angle	 X-ray	 scattering,	which	 failed	 to	 identify	 significant	 secondary	 structural	
features.	 	 Furthermore,	 minimal	 shifts	 in	 the	 spectroscopic	 features	 of	 α-synuclein	 were	
observed	 when	 the	 protein	 was	 placed	 in	 solutions	 that	 would	 increase	 hydrophobicity	 and	
neutralize	 negative	 charges	 indicating	 that	 the	 protein	 is	 natively	 unstructured,	 joining	 a	
growing	group	of	proteins	sharing	similar	biochemical	and	biophysical	characteristics	(Uversky	et	
al.,	2001b).		NMR	and	CD	data,	however,	indicated	that	α-synuclein	assumes	increasingly	folded	
secondary	 structure	when	 exposed	 to	 conditions	 that	 promote	 aggregation	 (low	 pH	 and	 high	
temperature)	 or	 upon	 interaction	 with	 phospholipids.	 	 Collectively	 these	 data	 indicated	 that	
native	α-synuclein	is	primarily	an	unstructured	monomer,	which	can	assume	different	compact	
conformations	that	resist	aggregation,	adopts	α-helical	conformation	upon	binding	to	lipids	and	
undergoes	 conformational	 changes	 prior	 to	 oligomerization	 and	 formation	 of	 amyloid	 fibrils	
(Uversky	 et	 al.,	 2001b).	 	 However,	 the	 methodologies	 employed	 to	 quantify	 the	 molecular	
weight	of	α-synuclein	in	these	elegant	studies	were	not	based	on	first	principles	and	therefore	a	
lingering	uncertainty	 remains	 regarding	 the	native	 size	of	 the	protein.	 	Moreover,	 crosslinking	




stabilization	 of	 high	molecular	weight	 α-synuclein	multimers	 (consistent	with	 dimers,	 trimers,	
and	 larger	 multimers).	 	 These	 multimers	 were	 not	 reduced	 by	 dilution	 of	 lysates	 before	









nm.	 	 Automated	 sampling	 of	 1000	 α-synuclein	 particles	 showed	 a	 distribution	 of	 molecular	
weights	between	10	and	175	kDa	with	a	peak	distribution	at	55	kDa.		These	findings	constitute	
the	most	direct	measurements	of	 the	native	molecular	weight	of	α-synuclein.	 	 The	 tetrameric	
species	were	shown	to	have	α-helical	conformation	and	were	resistant	to	aggregation	(Bartels	et	
al.,	2011).			
Complimentary	 observations	 were	 made	 using	 recombinant	 GST-tagged	 α-synuclein	 purified	
from	 bacterial	 expression	 systems	 under	 non-denaturing	 conditions.	 	 Single-particle	 electron	
microscopy	 of	 purified	 α-synuclein	 revealed	 complexes	 of	 sizes	 and	 internal	 geometries	
consistent	 with	 trimers	 and	 dimers,	 which	 were	 corroborated	 by	 measurements	 of	 the	
hydrodynamic	 radii	 and	 elution	 on	 native	 state	 PAGE.	 	 As	 observed	 previously,	 these	 species	
were	more	resistant	to	aggregation	than	denatured	monomer.		CD	also	showed	that	several	α-








majority	 remains	 as	 a	 disordered	 monomer	 (Gurry	 et	 al.,	 2013).	 	 These	 data	 indicated	 that	
several	potential	 conformers	of	α-synuclein	may	exist	 in	equilibrium.	 	The	observation	 that	α-
helical	 trimers	 and	 tetramers	 constitute	 only	 a	 small	 fraction	 of	 the	 total	 α-synuclein	 may	
explain	other	 studies	 in	which	 in-cell	NMR	was	used	 to	probe	 for	 the	 structure	of	α-synuclein	
and	 reported	 primarily	 the	 presence	 of	 unstructured	monomer.	 	 NMR	 data	 of	 α-synuclein	 in	
intact	cells	failed	to	detect	stable	or	highly	populated	α-synuclein	multimers	and	confirmed	the	
intrinsically	 disordered	 nature	 of	 the	 protein	 in	 E.	 coli	 regardless	 of	 its	 purification	 method	










synuclein	 is	 a	 monomer	 with	 minimal	 secondary	 structure	 (Fauvet	 et	 al.,	 2012a).	 	 Further	




predominant	 native	 form	 of	 α-synuclein	 is	 an	 unstructured	monomer.	 	 α-Synuclein	 exhibited	
random	coil	structure	in	solution,	readily	aggregated	over	time,	and	adopted	α-helical	structure	
only	upon	membrane	binding	(Burré	et	al.,	2013).			
α-Synuclein	 multimers	 were	 detected	 in	 postmortem	 non-diseased	 human	 brain	 using	 mild	
protein	 extraction	 methods,	 but	 no	 further	 purification.	 	 These	 α-synuclein	 multimers	 had	
Stokes	radii	ranging	from	33.2-37.5	Å,	sedimentation	coefficients	ranging	from	1.4S	to	3.8S	and	
apparent	molecular	weights	ranging	from	53-70	kDa	in	native	gradient	gels.		The	multimers	were	





the	 presence	 of	 α-synuclein	 conformers,	 defined	 as	 conformationally	 diverse	 α-synuclein	
multimers,	 in	 the	 human	 brain.	 	 Therefore	 it	 appears	 that	 both	 monomer	 and	 metastable	




these	multimeric	 α-synuclein	 conformers	 is	 to	 restrict	 recycling	 of	 synaptic	 vesicles	 and	 thus	
reduce	neurotransmitter	release	(Wang	et	al.	2014).			
Additional	 support	 for	 native	 multimeric	 species	 comes	 from	 recent	 studies	 in	 which	 serial	
purification	 of	 α-synuclein	 from	 non-pathological	 human	 cortical	 tissue	 was	 performed.		





in	 the	 isolation	 of	 >90%	 pure	 α-synuclein.	 	 Each	 step	 of	 serial	 purification	 resulted	 in	 a	
progressive	 loss	 of	 α-synuclein	 immunoreactive	 high	 molecular	 weight	 bands	 observed	 after	
disuccinimidyl	 glutarate	 crosslinking	 and	 SDS-PAGE	 separation.	 	 Analysis	 of	 α-synuclein	
secondary	 structure	 by	 CD	 found	 that	 the	 sequentially	 purified	 protein	 had	 greater	 α-helical	
content	than	the	recombinant	α-synuclein.	 	However,	a	high	degree	of	variability	 in	secondary	
structure	was	observed	between	purified	samples	raising	questions	about	the	stability	of	these	
helical	 conformations	 (Luth	et	al.,	2015).	 	 Furthermore,	 crosslinking	experiments	conducted	 in	
brain	tissue	from	mice	expressing	wildtype	or	A53T	human	α-synuclein	in	the	absence	of	mouse	






conformation	 through	 its	 association	with	 lipids	 has	 been	well	 documented.	 	 The	 association	
with	lipids	has	been	shown	to	prevent	fibril	formation	(Martinez	et	al.,	2007;	Zhu	and	Fink,	2003)	
and	 may	 also	 stabilize	 physiological	 multimeric	 species	 that	 together	 with	 the	 monomer	
regulate	SNARE	complex	assembly	and	recycling	of	synaptic	vesicles	(Burré	et	al.,	2014;	Wang	et	






α-synuclein	 is	 free	 in	 solution	 and	 can	 participate	 in	 nucleation	 (Galvagnion	 et	 al.,	 2015;	
Ysselstein	et	al.,	2015).		
In	 figure	 3	 we	 propose	 a	 model	 which	 incorporates	 and	 summarizes	 the	 existing	 knowledge	
regarding	α-synuclein	biology	and	structure.		The	steady	state	levels	of	α-synuclein	are	carefully	
regulated	 by	 protein	 synthesis	 and	 removal	 by	 several	 pathways	 such	 as	 the	 ubiquitin-
proteasome	pathways	and	autophagy	(Webb	et	al.,	2003).		Controlling	the	steady	state	levels	of	
this	 protein	 by	 regulating	 synthesis	 and	 degradation	 may	 be	 the	 first	 critical	 defense	 in	
preventing	aggregation.		Conformational	change	to	α-helical	rich	structures,	and	stabilization	of	
metastable	 multimers	 is	 achieved	 by	 specific	 interactions	 with	 vesicular	 phospholipids	 and	
proteins.	 	 The	 sequestration	 of	 α-synuclein	 in	 association	 with	 membrane	 vesicles	 and	 with	
other	 proteins	 may	 be	 of	 critical	 importance	 for	 preventing	 aggregation.	 	 Therefore	 these	
dynamic	 equilibria	 maintain	 functionality	 and	 promote	 assemblies	 that	 are	 resistant	 to	
aggregation.	 	 Catastrophic	 events	 that	 may	 include	 inappropriate	 post-translational	
modifications	 will	 disassemble	 the	 multimers	 as	 well	 as	 transform	 aggregation-incompetent	
monomers	 to	 aggregation-competent	 species.	 	 The	 first	 step	 in	 the	 pathway	 to	 amyloid	 fibril	
formation	is	the	generation	of	a	dimer	that	is	either	held	together	by	hydrophobic	interactions	
induced	 by	 increased	 conformational	 transition	 to	 β-sheet	 structure	 or	 upon	 covalent	 cross-
linking.	 	 Following	 this	 nucleation	 event	 (Wood	 et	 al.,	 1999)	 the	 hydrophobic	 patch	 of	 amino	
acids	 between	 residues	 71-82	 appears	 to	 be	 primarily	 responsible	 for	 allowing	 additional	 α-
synuclein	 monomers	 to	 assemble	 to	 form	 oligomeric	 structures.	 	 This	 transition	 is	 the	
committed	 rate	 limiting	 step	 for	 aggregation	 and	 must	 overcome	 a	 relatively	 large	
thermodynamic	requirement	that	permits	the	conversion	from	an	unstructured	coil	to	organized	




ring-like	 by	 atomic	 force	 and	 electron	microscopy	 (Conway	 et	 al.,	 2000;	 Lashuel	 et	 al.,	 2002).		




may	 continue	 to	 grow	 in	 linear	 β-sheets,	 forming	 polarized	 protofibrils	 and	 eventually	 fibrils.	
Fibrils	may	further	arrange	into	protein	inclusions	although	it	remains	unclear	if	other	proteins	
within	 these	 inclusions	 anchor	 these	 fibrils.	 	 Alternatively,	 oligomers	 may	 remain	 soluble	 by	
interacting	with	 small	molecules	 (Conway	et	al.,	 2001)	or	by	 incorporating	post-translationally	
modified	α-synuclein	molecules.	 	These	structures	remain	“off	the	amyloid	fibril	pathway”	and	
may	constitute	what	has	been	described	 in	human	postmortem	tissue	as	“dots”	or	“dust-like”	
amorphous	 aggregates	 (Braak	 et	 al.,	 2001;	 Duda	 et	 al.,	 2002).	 	 At	 this	 juncture,	 it	 remains	
unclear	 which	 of	 these	 assemblies	 are	 toxic	 to	 neurons.	 	 Recent	 data	 indicate	 that	 several	
conformationally	distinct	assemblies	(possibly	different	strains)	of	α-synuclein	generated	in	vitro	
will	 induce	the	aggregation	of	endogenous	α-synuclein	resulting	 in	neurodegeneration	(Guo	et	
al.,	 2013;	 Luk	 et	 al.,	 2012;	 Peelaerts	 et	 al.,	 2015;	 Sacino	 et	 al.,	 2014).	 	 The	 appreciation	 of	
different	 α-synuclein	 conformers	 and	 assemblies	 as	 well	 as	 their	 roles	 in	 disease	 may	 guide	
potential	 therapeutic	 approaches.	 	 For	 example,	 therapeutic	 strategies	 can	 be	 centered	 on	
preserving	 and	 stabilizing	 the	 physiological	 multimeric	 conformers	 as	 well	 as	 preventing	
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Figure 2.1.  Primary sequence of human α-synuclein.  Green color indicates the 
imperfect tandem repeats.  Known mutations are indicated in red.  The hydrophobic 
NAC domain is underlined.  The major sites of posttranslational modifications identified 
in vivo are highlighted in blue (Ac, acetylation; Ub, ubiquitination; NO2, nitration; and 
















Figure 2.2. The graph depicts the number of publications retrieved from PuBMed using 
the search term “alpha synuclein” from a single publication in 1998 to 862 in 2015.  
Significant milestones that examined the native structure and conformations of α-















Figure 2.3.  Free energy landscape of possible α-synuclein conformers and multimeric 
assemblies.  The conversion of native α-synuclein to aggregation-competent monomers 
may depend on dissociation from stabilizing interactions with lipids and/or proteins as 
well as dissociation of the metastable tetrameric species.  α-Synuclein aggregation-
competent monomers can then assemble into dimers and larger oligomeric conformers.  
The generation of α-synuclein oligomers can rapidly lead to formation of stable amyloid 
fibrils, or ‘off-pathway’ amorphous aggregates, both of which have been observed in 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.1 Summary and Conclusions 
	
Neurodegenerative	diseases	present	a	significant	challenge	for	healthcare	systems,	patients	
afflicted	by	these	diseases,	and	scientists	attempting	to	understand	their	underlying	
mechanisms	and	develop	disease-modifying	therapies.	As	populations	continue	to	age,	the	
burden	of	these	diseases	is	expected	to	worsen.	The	number	of	people	afflicted	with	dementia	
is	expected	to	rise	from	over	46	million	people	today	to	over	130	million	people	by	20181.	The	
total	cost	associated	with	treatment	and	care	is	expected	to	rise	from	$818	billion	today	to	over	
$1	trillion	in	20181.	The	development	of	effective	disease-modifying	therapies	to	treat	these	
diseases,	especially	Alzheimer’s	disease	(AD)	and	Parkinson’s	disease	(PD),	is	urgently	needed.		
AD	is	the	most	common	neurodegenerative	disease	and	the	most	common	cause	of	dementia,	
accounting	for	60%-80%	of	cases2.	In	the	United	States,	it	is	the	sixth	leading	cause	of	death	and	
afflicts	approximately	5.4	million	people.	This	is	expected	to	rise	to	13.8	million	people	by	2050.	
Age	is	the	greatest	risk	factor,	with	one	in	nine	people	over	the	age	of	65	diagnosed.	Of	the	top	
10	causes	of	death	in	the	United	States,	only	AD	cannot	be	prevented	or	delayed3.	Early	
symptoms	include	difficulty	remembering	recent	conversations,	and	apathy	and	depression.	
Later	symptoms	include	confusion,	disorientation,	poor	judgment	and	eventually	impaired	
ability	to	walk,	speak	and	eat.		
PD	afflicts	7-10	million	people	worldwide,	including	approximately	1	million	people	in	the	United	
States4.	The	lifetime	risk	of	developing	PD	is	1.5%5.	Like	AD,	the	greatest	risk	factor	is	age,	with	
the	median	onset	age	of	60	and	4	percent	of	cases	being	diagnosed	before	the	age	of	504.	Men	
are	50%	more	likely	to	develop	PD	than	women6.	Early	symptoms	of	PD	include	subtle	motor	
deficiencies,	including	changes	in	writing,	impairments	in	dexterity,	and	dragging	one	foot	while	
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walking7.	As	the	disease	progresses,	symptoms	include	bradykinesia,	resting	tremor,	rigidity	and	
slurred	speech.		
Underlying	the	pathology	of	both	AD	and	PD,	as	well	as	other	neurodegenerative	diseases	
including	Amyotrophic	Lateral	Sclerosis	and	Huntington’s	disease	(HD),	is	protein	aggregation8–
10.	Though	many	of	the	proteins	that	misfold	in	these	diseases	have	been	identified,	the	
relationship	between	this	misfolding	and	neurodegeneration	is	unclear.	Filling	this	gap	would	
shed	light	on	biological	pathways	and	molecular	targets	that	could	be	modified	to	mitigate	cell	
death	and	thus	provide	a	therapeutics	relief.	In	this	study,	we	focused	on	the	aggregation	of	α-
synuclein,	a	140	amino	acid	protein	that	has	roles	in	synaptic	plasticity11.	Aggregation	of	α-
synuclein	is	implicated	in	several	diseases,	collectively	known	as	synucleinopathies.	Prominent	
among	these	are	PD	and	dementia	with	Lewy	Bodies	(DLB).		
In	these	studies	we	aimed	to	quantitatively	investigate	the	effect	of	endogenous	aggregation	of	
α-synuclein	on	the	proteostasis	network	of	the	brain.	The	proteostasis	network	refers	to	the	
diverse	and	integrated	cellular	machinery	and	pathways	that	function	to	maintain	proper	
protein	homeostasis,	including	protein	localization,	expression,	degradation,	folding	and	binding	
partners12.	We	focused	on	changes	in	both	protein	and	phosphorylation	levels	to	study	how	the	
proteostasis	network	is	perturbed	due	to	α-synuclein	aggregation	in	the	brain.		
To	accomplish	this,	we	utilized	a	recently	developed	mouse	model	of	endogenous	α-synuclein	
that	recapitulates	several	cardinal	features	of	PD.	Aggregation	is	induced	in	this	model	by	
intrastriatal	injection	of	pre-formed	fibrils	(PFFs)	of	α-synuclein	into	non-transgenic	(WT)	mice13.	
This	aggregation	of	endogenous	α-synuclein	is	progressive,	spreading	from	near	the	site	of	
injection	to	synaptically	connected	regions	over	a	180-day	period.	Concomitant	with	this	
progressive	aggregation	is	dopaminergic	degeneration	and	the	onset	of	a	motor	phenotype,	
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both	cardinal	features	of	PD.	Importantly,	aggregation	(in	the	midbrain	and	striatum)	and	
dopaminergic	degeneration	is	confined	to	the	injected	side	only,	allowing	us	to	use	the	non-
injected	side	as	an	internal	control.	Finally,	injection	of	PFFs	into	α-synuclein-null	mice	(Snca	-/-)	
fails	to	induce	this	pathology,	allowing	us	to	use	these	mice	to	control	for	the	effect	of	the	
injection	on	protein	and	phosphorylation	levels.	We	used	a	modified	version	of	this	model	
whereby	mice	were	triple-injected	instead	of	single-injected	in	order	to	accelerate	pathology.	
Before	analyzing	these	mice	further,	we	validated	that	the	expected	differences	between	the	
injected	and	non-injected	sides,	and	between	the	WT	and	Snca	-/-	mice,	were	maintained.	We	
found	that	α-synuclein	phosphorylated	at	Ser-129,	a	marker	for	pathology14,15,	was	confined	to	
the	injected	side	of	WT	mice.	Additionally,	we	quantified	a	19%	loss	in	dopaminergic	neurons	in	
the	injected	side	of	WT	mice	compared	with	the	non-injected	side,	versus	no	loss	in	the	Snca	-/-	
mice.	After	confirming	these	findings,	employed	a	quantitative	mass	spectrometry	(MS)-based	
approach	to	measure	the	relative	abundance	changes	in	protein	and	phosphorylation	levels	due	
to	α-synuclein	aggregation.	
Our	work	quantified	the	relative	abundance	changes	of	5,290	proteins	in	WT	and	3,335	proteins	
in	Snca	-/-	mice	and	2,983	phosphorylation	sites	in	WT	and	2,112	phosphorylation	sites	in	Snca	-
/-.	Comparing	the	quantified	proteins	in	our	work	to	proteins	identified	in	the	mouse	brain	in	
MS-based	studies	in	the	literature16–19	revealed	no	major	differences	in	terms	of	molecular	
weight,	biological	function	or	cellular	localizations.	This	adds	confidence	that	the	proteins	
quantified	in	our	study	do	not	significantly	differ	from	those	found	in	other	studies.	Additionally,	
there	were	significant	declines	in	the	relative	abundance	of	proteins	selectively	expressed	in	
dopaminergic	neurons	in	WT	but	not	Snca	-/-	mice,	including	tyrosine	hydroxylase	(TH),	
aromatic-L-amino-acid	decarboxylase	(Addc),	synaptic	vesicular	amine	transporter-2	(VMAT2),	
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and	dopamine	transporter	(DAT).	The	declines	in	TH,	Addc	and	VMAT2	were	validated	by	
Western	blot,	adding	further	confidence	in	our	model	and	approach.	Collectively,	these	analyses	
demonstrate	the	comprehensiveness	and	selectivity	of	our	approach,	and	add	confidence	in	our	
findings.		
Statistical	analysis	of	the	quantified	proteins	and	phosphosites	resulted	in	the	identification	of	
311	proteins	(152	that	increased	and	159	that	decreased	in	the	injected	side)	and	133	
phosphosites	(from	121	phosphoproteins)	whose	relative	abundance	significantly	changed.	Of	
the	proteins	that	significantly	changed,	we	found	that	RNA	transport	and	the	immune	response	
were	enriched	among	the	proteins	that	increased	in	the	injected	side,	and	that	vesicle-mediated	
transport,	ion	transmembrane	transport	and	microtubule	organization	was	enriched	in	the	
proteins	that	decreased.	Among	the	phosphoproteins	that	significantly	changed,	vesicle-
mediated	transport	and	membrane	organization	were	enriched.	For	the	phosphoproteins	we	did	
not	separate	the	phosphosites	that	increased	and	decreased	since	the	direction	of	the	change	in	
relative	abundance	is	not	necessarily	indicative	of	the	change	in	activity	(i.e.	and	increase	in	
phosphorylation	does	not	necessarily	mean	an	increase	in	activity).	These	enrichment	analyses	
from	the	proteomics	and	phosphoproteomics	suggest	that	cellular	signaling	is	perturbed	in	
response	to	α-synuclein	aggregation,	consistent	with	the	documented	dopaminergic	
degeneration	in	this	model	and	data	from	other	studies13,20–22.		
Of	the	311	proteins	and	135	phosphosites	that	significantly	changed,	we	decided	to	focus	on	
Lmp7	(also	known	as	proteasome	subunit	beta	8,	or	psmb8)	for	three	reasons.	First,	it	had	the	
greatest	increase	of	the	152	proteins	that	significantly	increased	(236%).	Second,	it	is	involved	in	
the	immune	response,	a	topic	that	has	garnered	increased	attention	as	a	potential	mediator	of	
α-synuclein	aggregation-mediated	toxicity	in	PD23.	And	finally,	it	is	a	catalytic	subunit	of	the	
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immunoproteasome,	which	has	been	implicated	in	protein	aggregation	diseases	including	AD	
and	HD24–26,	but	not	in	synucleinopathies.	We	first	validated	the	increase	detected	by	
proteomics	by	Western	blot.	Then,	using	human	DLB	samples,	we	found	that	Lmp7	levels	and	
activity	were	elevated	in	disease	compared	with	healthy	controls.	This	is,	to	our	knowledge,	the	
first	reported	association	between	the	immunoproteasome	and	synucleinopathies.		
Lmp7	is	one	of	the	three	cardinal	subunits	of	the	immunoproteasome.	Upon	stimulation	by	
proinflammatory	cytokines	or	oxidative	stress,	expression	of	the	catalytic	subunits	of	the	
immunoproteasome,	namely	Lmp2,	MECL-1	and	Lmp7,	is	elevated27,28.	These	proteins	then	
replace	the	catalytic	subunits	of	the	constitutive	proteasome,	namely	β1,	β2	and	β5,	respectively.	
The	immunoproteasome,	which	has	different	cleavage	site	preferences	and	catalytic	activity	
than	the	constitutive	proteasome,	generates	antigenic	peptides	that	are	recognized	by	MHC	
class	I	molecules29–32.	These	MHC	class	I	molecules	then	present	these	peptides	on	the	cell	
surface	for	detection	and	destruction	by	CD8+	T	cells33.	
Though	the	immunoproteasome	has	not	been	directly	linked	to	synucleinopathies,	a	recent	
study	found	a	link	between	MHC-I	and	dopaminergic	neurons34.	This	study	documented	the	
expression	of	MHC-I	in	the	substantia	nigra	of	both	control	and	PD	samples	leading	to	a	
proposed	model	that	links	MHC-I	and	dopaminergic	degeneration.	In	this	model,	IFNγ	induced	
by	the	aggregation	α-synuclein	and	the	oxidative	stress	caused	by	cytosolic	dopamine	results	in	
the	expression	of	MHC-I.	This	MHC-I	is	then	loaded	with	antigenic	peptides	and	exposed	on	the	
cell	surface	for	destruction	by	cytotoxic	T	cells	(CTLs).	Though	the	endogenous	source	of	these	
peptides	was	not	considered,	our	work	may	provide	the	link.		
The	oxidative	stress	and	IFNγ	results	in	the	increased	expression	of	the	immunoproteasome,	as	
we	document	in	our	studies.	The	immunoproteasome	then	interacts	with	and	degrades	α-
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synuclein	fibrils	more	efficiently	than	the	constitutive	proteasome.	This	is	consistent	with	the	
documented	preference	of	the	immunoproteasome	to	degrade	basic	proteins35.	Furthermore,	in	
our	studies	using	cell	free	systems,	we	demonstrate	that	degradation	of	α-synuclein	fibrils	
occurs	more	rapidly	by	the	immunoproteasome	than	the	constitutive	proteasome.	Furthermore,	
the	products	of	this	degradation	reaction	are	unable	to	accelerate	the	aggregation	of	soluble	α-
synuclein,	a	feature	of	bona	fide	protein	aggregates9.	The	resulting	α-synuclein	peptides	are	
then	loaded	onto	the	MHC-I	molecules	for	presentation	to	CTLs.	Thus,	dopaminergic	neuron	
degeneration	in	synucleinopathies	may	be	enhanced	by	accelerated	degradation	of	α-synuclein	
by	the	immunoproteasome,	leading	to	MHC-1	presentation	on	the	cell	surface,	and	recognition	
by	CTLs.		
Alternatively,	the	degradation	of	α-synuclein	fibrils	by	the	immunoproteasome	could	be	
neuroprotective.	Though	there	is	debate	as	to	whether	the	aggregation	of	α-synuclein	causes	
cell	death	via	a	toxic	gain-of-function	or	a	toxic	loss-of-function36,	the	finding	that	α-synuclein-
null	mice	are	viable	and	do	not	have	shortened	lifespan	supports	a	toxic	gain-of-function37,38.	
Not	surprisingly,	many	therapeutic	strategies	have	attempted	to	remove	α-synuclein	aggregates	
as	a	protective	mechanism39.	These	include	immunization	against	α-synuclein40,41,	small	
molecule	inhibition	of	aggregation42,43,	and	the	exogenous	introduction	of	protein	
disaggregases44.	This	last	approach	is	particularly	troublesome	given	the	difficulty	in	introducing	
these	proteins	intracellularly	and	the	cofactors	that	are	needed	for	these	large	protein	
complexes	to	function.	The	immunoproteasome	may	provide	a	novel,	endogenous	therapeutic	
target	that	can	be	modulated	to	mitigate	α-synuclein-mediated	neurodegeneration.	
Augmentation	of	the	immunoproteasome	could	accelerate	α-synuclein	degradation	and	thus	
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retard	neuron	death.	Additionally,	engineering	of	the	immunoproteasome	may	increase	the	
activity	and	selectivity	for	α-synuclein	aggregates.		
Determination	of	the	role	of	the	immunoproteasome	in	enhancing	or	mitigating	
synucleinopathies	is	critical	for	the	ultimate	goal	of	therapeutic	development.	A	key	tool	that	
could	be	used	to	test	this	is	the	immunoproteasome-null	mouse.	These	mice	lack	all	three	
catalytic	subunit	of	the	immunoproteasome	and	exhibit	the	expected	defects	in	presenting	
several	classes	of	MHC-I	epitopes45.	Injection	of	PFFs	into	these	mice	followed	by	monitoring	of	
motor	symptoms,	dopaminergic	degeneration,	and	α-synuclein	aggregation	would	clarify	the	
role	of	the	immunoproteasome.	We	expect	decreased	α-synuclein-positive	aggregates	in	the	
immunoproteasome-null	injected	mice.	While	enhanced	dopaminergic	degeneration	and	motor	
symptoms	would	suggest	a	neuroprotective	role	for	the	immunoproteasome,	decreased	
degeneration	and	motors	symptoms	would	be	evidence	for	a	neurotoxic	role.		
Ultimately,	our	work	contributes	three	major	new	findings.	First,	we	further	characterized	an	
important	mouse	model	of	α-synuclein	aggregation	that	will	assist	future	researchers	using	this	
model.	Second,	we	provide	a	rich	source	of	the	relative	abundance	changes	of	proteins	and	
phosphosites	in	the	brain	in	response	to	the	endogenous	aggregation	of	α-synuclein.	This	could	
provide	a	valuable	resource	for	investigators	studying	how	proteostasis	pathways	respond	to	α-
synuclein	aggregation	specifically,	or	protein	aggregation	broadly.	Finally,	we	document,	for	the	
first	time,	an	increase	in	the	levels	and	activity	of	the	immunoproteasome	in	a	human	
synucleinopathy,	and	explore	its	activity	against	α-synuclein	fibrils	compared	with	the	
constitutive	proteasome.	We	believe	the	immunoproteasome	is	a	putative	therapeutic	target	
for	treating	synucleinopathies	like	PD	and	DLB,	and	merits	further	attention.		
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